Fasudil
Phase 2Small molecule
Fasudil is one of 51 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 2.
2
Indications
7
Total Trials
2
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
55 competitors in Amyotrophic Lateral Sclerosis
#DrugCompanyPhaseTrials
1Nourianz
Kyowa Kirin Co., Ltd.Approved
Vimpat
UCBApproved
Enablex
AbbVieApproved
Bosulif
PPrism Pharmaceuticals
Approved
Quinidine Gluconate
WWyeth-Lederle Vaccines
Approved
Transderm Scop
BBaxter Healthcare Corporation
Approved
Mirapex
Boehringer IngelheimApproved
Rapamune
PPrism Pharmaceuticals
Approved
Avodart
Akero TherapeuticsApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment2 trials
Amyotrophic Lateral Sclerosis2 trials
Vascular Function1 trial
The Effect of Fasudil on Vascular Function in Humans
Completed·—·Phase 2·NCT00120718·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fasudil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- WWoolsey Pharmaceuticals